Inovelon

Rufinamide, the active ingredient in Inovelon, is an antiepileptic presented as an oral tablet for oral use. It is indicated for the treatment of seizures associated with Lennox‑Gastaut syndrome in patients for whom other therapies are insufficient.

GNH USA supplies Inovelon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rufinamide is used in the management of seizure disorders, particularly those classified under the Lennox‑Gastaut syndrome spectrum.

- Lennox‑Gastaut syndrome: reduces the frequency of drop attacks and other seizure types. - Adjunctive therapy for refractory epilepsy: provides additional seizure control when combined with other antiepileptics. - Multiple seizure types: helps lower overall seizure burden in patients with mixed seizure presentations.

Rufinamide may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe depression or suicidal thoughts - Hepatic dysfunction

Before initiating therapy with Rufinamide, consider the following safety measures.

- Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: unknown effects; evaluate risk‑benefit ratio. - Renal impairment: monitor renal function and adjust dose if necessary. - Hepatic impairment: assess liver enzymes regularly. - Concomitant enzyme‑inducing antiepileptics: may reduce Rufinamide efficacy. - Store at ambient temperature: keep below 25°C, protect from moisture and store in original packaging.

Rufinamide can interact with several medications, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: strong enzyme inducer that markedly lowers Rufinamide plasma levels. - Phenobarbital: reduces Rufinamide exposure, potentially diminishing seizure control. - Phenytoin: decreases Rufinamide concentrations, risking therapeutic failure.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may experience reduced efficacy when combined with Rufinamide. - Valproate: can increase the risk of adverse effects such as dizziness and fatigue. - CYP3A4 inhibitors (e.g., ketoconazole): may raise Rufinamide levels, requiring careful monitoring.